The Competition Commission of India (CCI) has raised concerns over the proposed merger between Torrent Pharmaceuticals and JB Chemicals, pointing to potential monopoly risks in key therapeutic segments. The antitrust watchdog believes the deal could significantly reduce competition and distort pricing dynamics in the domestic pharmaceutical market.

According to sources familiar with the development, the CCI has sought additional details from both companies regarding their product overlaps and market share. The regulator is particularly examining two drug categories — Nifedipine, used to treat hypertension, and Lactobacillus, a probiotic formulation — where the combined market share could exceed 70 to 90 per cent post-merger.

Officials say such concentration levels could limit competition

See Full Page